Navigation Links
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Date:3/18/2008

CV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks re
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
2. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
8. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
9. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
10. Smithfield Foods, Inc. Statement Regarding Animal Cloning
11. Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... University of Oregon chemist Geraldine Richmond, have tapped ... synthetic proteins called peptoid nanosheets that mimic complex ... detailed this week in a paper placed online ... the National Academy of Sciences -- is ... two-dimensional peptoid nanosheets that can be used in ...
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma ... a recommended approach for protecting personal data in ... researchers, patients and others. The document describes an ... information from CSRs and other related clinical trial ... The goal of the TransCelerate CSR Redaction ...
(Date:9/2/2014)... 02, 2014 Opertech Bio, Inc., ... efficient, cost effective approach to sensory evaluation, today ... by the U.S. Patent and Trademark Office, encompassing ... , “Opertech’s taste evaluation technology called Microtiter ... high throughput system for rapid characterization of taste ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... drug discovery and development services, cell lines, and reagents ... Feb. 26 The leading experts in ion channels ... discovery, development, and safety - are now united. ChanTest, ... validated cell lines, announced that it has acquired Rockville, ...
... the availability of Trade Alerts on stocks making news today. ... free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: ... Industries Ltd. (Nasdaq: TEVA ), Allergan Inc. (NYSE: ... ), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX ) and ...
... announced today that it has received U.S. Food and ... using the Biomerix Biomaterial(TM), REVIVE acts as a tissue ... in a variety of soft tissue repair procedures, including ... procedures per year, inguinal hernia repair is one of ...
Cached Biology Technology:ChanTest Acquires Applied Cell Sciences 2ChanTest Acquires Applied Cell Sciences 3ChanTest Acquires Applied Cell Sciences 4Beacon Equity Issues Technical Trade Alerts on Drug Manufacturer Stocks: FRX, TEVA, AGN, CEPH, VRTX, ADLR 2Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures 2
(Date:9/1/2014)... television making us fat? An increasing amount of research ... consumption and a more sedentary lifestyle. Now, a new ... is alike. Some TV programs might lead people to ... that if you,re watching an action movie while snacking ... Tal, Ph.D. lead author on the new article just ...
(Date:9/1/2014)... Conventional wisdom has long held that corals ... reefs are passive organisms that rely entirely ... as nutrients and oxygen. But now scientists at ... in Israel have found that they are far ... into turbulent patterns that greatly enhance their ability ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Nature's tiny engineers 2Nature's tiny engineers 3A nucleotide change could initiate fragile X syndrome 2
... longest in the animal kingdom and they have largely ... scientists led by the University of Exeter have uncovered ... Africa and the results could have huge implications for ... the journal Current Biology, Dr Brendan Godley and an ...
... international team of scientists reported evidence, in a controversial cover ... more than 3.8 billion years ago--400 million years earlier than ... that team and two of the original authors will report ... , Craig E. Manning, lead author of the new study ...
... mouse is providing hope of a new treatment for ... transmission of serotonin in the brain. Serotonin is known ... sexuality. By breeding mice with an absence of TREK-1, ... of this research, which involved an international collaboration with ...
Cached Biology News:How satellite tracking revealed the migratory mysteries of endangered Atlantic loggerhead turtles 2UCLA scientists strengthen case for life more than 3.8 billion years ago 2UCLA scientists strengthen case for life more than 3.8 billion years ago 3UCLA scientists strengthen case for life more than 3.8 billion years ago 4UCLA scientists strengthen case for life more than 3.8 billion years ago 5Ever-happy mice may hold key to new treatment of depression 2
... Pig serum is collected from fasted Guinea Pigs. ... Citrate N-04: Heparin (Na) N-06: ... N-10: EDTA (Na) N-03: Alsevers ... N-09: K3EDTA N-11: Heparin ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
... precipitation offers major advantages over other RNA precipitation ... protein or carbohydrates. It is the method of ... synthesis from RNA preparations. Note, LiCl precipitation may ... isolations. If the RNA is to be used ...
Biology Products: